Manakova or Lehtonen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4816093/publications.pdf

Version: 2024-02-01

50 papers

1,991 citations

304743 22 h-index 265206 42 g-index

57 all docs

57 docs citations

57 times ranked

3115 citing authors

#	Article	IF	CITATIONS
1	The iPSC perspective on schizophrenia. Trends in Neurosciences, 2022, 45, 8-26.	8.6	24
2	Microglia-like Cells Promote Neuronal Functions in Cerebral Organoids. Cells, 2022, 11, 124.	4.1	50
3	CNS Redox Homeostasis and Dysfunction in Neurodegenerative Diseases. Antioxidants, 2022, 11, 405.	5.1	11
4	Contribution of astrocytes to familial risk and clinical manifestation of schizophrenia. Glia, 2022, 70, 650-660.	4.9	12
5	Microglial amyloid beta clearance is driven by PIEZO1 channels. Journal of Neuroinflammation, 2022, 19, .	7.2	45
6	Metabolic and immune dysfunction of glia in neurodegenerative disorders: Focus on iPSC models. Stem Cells, 2021, 39, 256-265.	3.2	7
7	Studying non–cell-autonomous neurodegeneration in Parkinson's disease with induced pluripotent stem cells. , 2021, , 251-276.		O
8	An arylthiazyne derivative is a potent inhibitor of lipid peroxidation and ferroptosis providing neuroprotection in vitro and in vivo. Scientific Reports, 2021, 11, 3518.	3.3	20
9	Utilising Induced Pluripotent Stem Cells in Neurodegenerative Disease Research: Focus on Glia. International Journal of Molecular Sciences, 2021, 22, 4334.	4.1	14
10	Molecular signaling pathways underlying schizophrenia. Schizophrenia Research, 2021, 232, 33-41.	2.0	14
11	Blood–Brain Barrier and Neurodegenerative Diseases—Modeling with iPSC-Derived Brain Cells. International Journal of Molecular Sciences, 2021, 22, 7710.	4.1	36
12	Neurobiological roots of psychopathy. Molecular Psychiatry, 2020, 25, 3432-3441.	7.9	21
13	NFâ€E2â€related factor 2 activation boosts antioxidant defenses and ameliorates inflammatory and amyloid properties in human Presenilinâ€1 mutated Alzheimer's disease astrocytes. Glia, 2020, 68, 589-599.	4.9	27
14	Generation of a human induced pluripotent stem cell line (UEFi003-A) carrying heterozygous A673T variant in amyloid precursor protein associated with a reduced risk of Alzheimer's disease. Stem Cell Research, 2020, 48, 101968.	0.7	5
15	Proteostasis Disturbances and Inflammation in Neurodegenerative Diseases. Cells, 2020, 9, 2183.	4.1	26
16	Metabolic alterations in Parkinson's disease astrocytes. Scientific Reports, 2020, 10, 14474.	3.3	104
17	A CX3CR1 Reporter hESC Line Facilitates Integrative Analysis of In-Vitro-Derived Microglia and Improved Microglia Identity upon Neuron-Glia Co-culture. Stem Cell Reports, 2020, 14, 1018-1032.	4.8	16
18	Altered Brain Endothelial Cell Phenotype from a Familial Alzheimer Mutation and Its Potential Implications for Amyloid Clearance and Drug Delivery. Stem Cell Reports, 2020, 14, 924-939.	4.8	63

#	Article	IF	Citations
19	O7.7. NEUROBIOLOGICAL ROOTS OF SCHIZOPHRENIA. Schizophrenia Bulletin, 2019, 45, S182-S182.	4.3	O
20	Sex-specific transcriptional and proteomic signatures in schizophrenia. Nature Communications, 2019, 10, 3933.	12.8	41
21	PSEN1ΔE9, APPswe, and APOE4 Confer Disparate Phenotypes in Human iPSC-Derived Microglia. Stem Cell Reports, 2019, 13, 669-683.	4.8	132
22	Astrocyte alterations in neurodegenerative pathologies and their modeling in human induced pluripotent stem cell platforms. Cellular and Molecular Life Sciences, 2019, 76, 2739-2760.	5.4	88
23	Dysfunction of Cellular Proteostasis in Parkinson's Disease. Frontiers in Neuroscience, 2019, 13, 457.	2.8	95
24	Long-term interleukin-33 treatment delays disease onset and alleviates astrocytic activation in a transgenic mouse model of amyotrophic lateral sclerosis. IBRO Reports, 2019, 6, 74-86.	0.3	18
25	Generation of a human induced pluripotent stem cell line from a patient with a rare A673T variant in amyloid precursor protein gene that reduces the risk for Alzheimer's disease. Stem Cell Research, 2018, 30, 96-99.	0.7	9
26	Structural Immaturity of Human iPSC-Derived Cardiomyocytes: In Silico Investigation of Effects on Function and Disease Modeling. Frontiers in Physiology, 2018, 9, 80.	2.8	110
27	Generation of a human induced pluripotent stem cell line (LL008 1.4) from a familial Alzheimer's disease patient carrying a double KM670/671NL (Swedish) mutation in APP gene. Stem Cell Research, 2018, 31, 181-185.	0.7	7
28	Identification of mechanisms leading to blood-brain barrier dysfunction in Parkinson's disease. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-1-124.	0.0	0
29	PSEN1 Mutant iPSC-Derived Model Reveals Severe Astrocyte Pathology in Alzheimer's Disease. Stem Cell Reports, 2017, 9, 1885-1897.	4.8	239
30	[P3–170]: HUMAN IPSCâ€DERIVED ALZHEIMER's DISEASE ASTROCYTES RECAPITULATE DISEASEâ€RELATED PHENOTYPES. Alzheimer's and Dementia, 2017, 13, P999.	0.8	0
31	Creation of a library of induced pluripotent stem cells from Parkinsonian patients. Npj Parkinson's Disease, 2016, 2, 16009.	5.3	74
32	Inhibition of Excessive Oxidative Protein Folding Is Protective in MPP ⁺ Toxicity-Induced Parkinson's Disease Models. Antioxidants and Redox Signaling, 2016, 25, 485-497.	5.4	26
33	Pyrrolidine dithiocarbamate activates the Nrf2 pathway in astrocytes. Journal of Neuroinflammation, 2016, 13, 49.	7.2	38
34	ADAMTS-4 promotes neurodegeneration in a mouse model of amyotrophic lateral sclerosis. Molecular Neurodegeneration, 2016, 11, 10.	10.8	25
35	Transplanted Human Induced Pluripotent Stem Cell-Derived Neural Progenitor Cells Do Not Promote Functional Recovery of Pharmacologically Immunosuppressed Mice with Contusion Spinal Cord Injury. Cell Transplantation, 2015, 24, 1799-1812.	2.5	40
36	Immunomodulation by interleukin-33 is protective in stroke through modulation of inflammation. Brain, Behavior, and Immunity, 2015, 49, 322-336.	4.1	107

#	Article	IF	Citations
37	Interleukin-33 treatment reduces secondary injury and improves functional recovery after contusion spinal cord injury. Brain, Behavior, and Immunity, 2015, 44, 68-81.	4.1	105
38	Nrf2 Regulates Neurogenesis and Protects Neural Progenitor Cells Against A \hat{l}^2 Toxicity. Stem Cells, 2014, 32, 1904-1916.	3.2	110
39	Tyrosine hydroxylase gene transfections to different sites of striatum in the rat model of Parkinson's disease. Open Journal of Genetics, 2013, 03, 30-37.	0.1	0
40	Production of monocytic cells from bone marrow stem cells: therapeutic usage in Alzheimer's disease. Journal of Cellular and Molecular Medicine, 2012, 16, 1060-1073.	3.6	26
41	Aflatoxin B1 – a potential endocrine disruptor – up-regulates CYP19A1 in JEG-3 cells. Toxicology Letters, 2011, 202, 161-167.	0.8	50
42	Expression of tyrosine hydroxylase in the striatum of atipamezole-treated rats. European Journal of Pharmaceutical Sciences, 2009, 36, 602-604.	4.0	1
43	Lack of robust protective effect of quercetin in two types of 6-hydroxydopamine-induced parkinsonian models in rats and dopaminergic cell cultures. Brain Research, 2008, 1203, 149-159.	2.2	42
44	Different viabilities and toxicity types after 6-OHDA and Ara-C exposure evaluated by four assays in five cell lines. Toxicology in Vitro, 2008, 22, 182-189.	2.4	22
45	A prolyl oligopeptidase inhibitor, Z-Pro-Prolinal, inhibits glyceraldehyde-3-phosphate dehydrogenase translocation and production of reactive oxygen species in CV1-P cells exposed to 6-hydroxydopamine. Toxicology in Vitro, 2006, 20, 1446-1454.	2.4	32
46	Failure of FK506 (tacrolimus) to alleviate apomorphine-induced circling in rat Parkinson model in spite of some cytoprotective effects in SH-SY5Y dopaminergic cells. Brain Research, 2005, 1038, 83-91.	2.2	14
47	The roles of dopamine transporter and Bcl-2 protein in the protection of CV1-P cells from 6-OHDA-induced toxicity. Toxicology Letters, 2004, 154, 117-123.	0.8	20
48	Increased p53 levels without caspase-3 activity and change of cell viability in 6-hydroxydopamine-treated CV1-P cells. Cell Biology and Toxicology, 2003, 19, 177-187.	5.3	8
49	Nontargeted Metabolite Profiling of Induced Pluripotent Stem Cells (iPSCs) Derived Neural Cells: Insights Into Mechanisms of Brain Diseases. , 0, , .		0
50	Microglia Orchestrate Neuronal Activity in Brain Organoids. SSRN Electronic Journal, 0, , .	0.4	2